Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6871.

https://doi.org/10.1182/blood-2023-188830

Published: 2023

Journal Articles

Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety

Fabian Mueller, Julie Rytlewski, Chun Wu, Sarah Hu, Ashley Koegel, Nikolay Delev, Ana Kostic, Vaishali Shah, Thomas Wegman, Georg Schett

Blood (2023) 142 (Supplement 1): 6873.

https://doi.org/10.1182/blood-2023-174276

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Blood (2023) 142 (Supplement 1): 220.

https://doi.org/10.1182/blood-2023-180547

Published: 2023

Journal Articles

Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Franziska Gsottberger, Christina Meier, Anna Ammon, Scott Parker, Kerstin Wendland, Rebekka George, Srdjan Petkovic, Lisa Mellenthin, Charlotte Emmerich, Gloria Lutzny-Geier, Markus Metzler, Andreas Mackensen, Vidyalakshmi Chandramohan, Fabian Mueller

Blood (2022) 140 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2022-169012

Published: 2022

Journal Articles

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Hannah Reimann, Anita Natalie Kremer, Viktoria Blumenberg, Katja Schmidt, Michael Aigner, Andreas Kremer, Matthias Tenbusch, Heiko Bruns, Thomas Harrer, Georg Schett, Fabian Mueller, Andreas Mackensen, Marion Subklewe, Simon Voelkl

Blood (2022) 140 (Supplement 1): 10279–10280.

https://doi.org/10.1182/blood-2022-165968

Published: 2022

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Fabian Mueller, Simon Voelkl, Dimitrios Mougiakakos, Sebastian Boeltz, Michael Aigner, Regina Gary, Sascha Kretschmann, Soraya Kharboutli, Arnd Kleyer, David Simon, Wolf Rösler, Katharina M. Habenicht, Thomas H. Winkler, Gerhard Krönke, Georg Schett, Andreas Mackensen

Blood (2022) 140 (Supplement 1): 4562–4563.

https://doi.org/10.1182/blood-2022-165077

Published: 2022

Journal Articles

CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Blood (2022) 140 (Supplement 1): 10407–10409.

https://doi.org/10.1182/blood-2022-156775

Published: 2022

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Fabian Mueller, MD, Tyler Cunningham, Stephanie Stookey, Chin-Hsien Tai, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2016) 128 (22): 2810.

https://doi.org/10.1182/blood.V128.22.2810.2810

Published: 2016

Journal Articles

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

Fabian Mueller, MD PhD, Xiu-Fen Liu, PhD, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2015) 126 (23): 1332.

https://doi.org/10.1182/blood.V126.23.1332.1332

Published: 2015

Journal Articles

B-Cell Receptor Recognition of Multiple Epitopes Correlates with An Aggressive Clinical Course of Chronic Lymphocytic Leukemia.

Mascha Binder, MD, Antje Jackst, Barbara Léchenne, Fabian Mueller, Hendrik Veelken, Roland H. Mertelsmann, MD, PhD, Martin Trepel

Blood (2009) 114 (22): 56.

https://doi.org/10.1182/blood.V114.22.56.56

Published: 2009

Journal Articles

Age-Stratified Treatment-Modalities for Patients with Primary CNS Lymphoma: Results of a Phase II Study and Two Pilot-Studies.

Gerald Illerhaus, MD, Reinhard Marks, MD, Fabian Mueller, Friedrich Feuerhake, MD, Christoph Ostertag, MD, Jurgen Finke, MD

Blood (2006) 108 (11): 4683.

https://doi.org/10.1182/blood.V108.11.4683.4683

Published: 2006

NARROW

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

B-Cell Receptor Recognition of Multiple Epitopes Correlates with An Aggressive Clinical Course of Chronic Lymphocytic Leukemia.

Age-Stratified Treatment-Modalities for Patients with Primary CNS Lymphoma: Results of a Phase II Study and Two Pilot-Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only